Celgene (CELG) Sank To A 4-Month Low After Crohn's Disease Treatment Abandoned

Celgene Corp. (CELG) announced after the bell Thursday that it has decided to discontinue its Phase 3 study of GED-0301 for the treatment of Crohn's disease based on the recommendation of the Data Monitoring Committee.

from RTT - Before the Bell http://ift.tt/2l9oPNV
via IFTTT